News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Article

Pharmaceutical Executive

January 14, 2013

R&D Trends for 2013: Data Trims, Partnerships, and Emerging Global Players

Author(s):

Clark Herman

The Tufts Center for the Study of Drug Development (CSDD) sees two key trends as increasingly important for pharmaceutical companies to maintain success:

The Tufts Center for the Study of Drug Development (CSDD) sees two key trends as increasingly important for pharmaceutical companies to maintain success: eliminating the bane of extraneous data and fostering collaborations with academia and multi-company consortia both as measures of reducing costs and remaining competitive by more quickly and effectively guiding medicines to market. Additionally, a new event on the horizon is the emergence of foreign players in key markets determined to steal a page from big pharma’s playbook.

According to the latest Tufts CSDD Outlook , eliminating non-core procedures from development pipelines could generate anywhere from four to six billion dollars in savings for the industry. To that end, many companies have adopted sophisticated statistical analyses and have increased use of biomarkers to increase their understanding of what data they generate to improve speed to market.

Trends also point to newer collaboration models being used that foster competition among academic institutions to generate solid leads for novel therapies in exchange for research grants from drug companies. As Kenneth Kaitin, Professor and Director of CSDD explains, “This new academic-industry relationship works out for companies who can incentivize multiple projects before fully entering into contracts that limit the possibilities to the findings of just one school, and it also works out for academics seeking to gain access to industry-exclusive tools as well as areas where pharma holds expertise.” Other tactics gaining prevalence are the establishment of multi-company consortia, many of which center around specific therapeutic areas as a way to effectively address areas of unmet need.

Also events coming to fruition in 2013: Kaitin points to companies from China, India, and other non-western countries emerging to introduce medicines to the global market. For example, he says, “China’s State Food and Drug Administration (SFDA) is aware of the need to be a more active player in the world pharmaceutical market and knows the only way to do that is to improve the regulatory environment for companies to conduct clinical research there. When you look at the size of the population and the opportunity for growth of western medicine in those regions, they are not that far off in solving the problem.”

In the coming year, Tufts CSDD research priorities will look at evaluating best practices in improving minority patient participation, evaluating costs of regulatory harmonization, and assessing reasons why investigational drugs fail.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
Stock.adobe.com
August 27th 2025

FDA Accepts New Drug Application for Gadoquatrane

Nicholas Jacobus
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 27th 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Stock.adobe.com
August 27th 2025

ACOG Breaks From CDC, Reaffirms Support of Covid-19 Vaccine During Pregnancy

Nicholas Jacobus
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 27th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
EVERSANA and Waltz Health Unite to Address Drug Pricing and Access Issues
August 27th 2025

EVERSANA and Waltz Health Unite to Address Drug Pricing and Access Issues

Nicholas Saraceno, Editor
Stock.adobe.com
August 27th 2025

Eli Lilly’s Orforglipron Successfully Completes Third Phase 3 Trial Resulting in Global Regulatory Submissions

Nicholas Jacobus
Related Content
Advertisement
Stock.adobe.com
August 27th 2025

FDA Accepts New Drug Application for Gadoquatrane

Nicholas Jacobus
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 27th 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Stock.adobe.com
August 27th 2025

ACOG Breaks From CDC, Reaffirms Support of Covid-19 Vaccine During Pregnancy

Nicholas Jacobus
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 27th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
EVERSANA and Waltz Health Unite to Address Drug Pricing and Access Issues
August 27th 2025

EVERSANA and Waltz Health Unite to Address Drug Pricing and Access Issues

Nicholas Saraceno, Editor
Stock.adobe.com
August 27th 2025

Eli Lilly’s Orforglipron Successfully Completes Third Phase 3 Trial Resulting in Global Regulatory Submissions

Nicholas Jacobus
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.